 | ||
 |
 |
 |
 |
 |
 |
|
KANE BIOTECH INC. is a biotechnology company engaged in the development of products to prevent and disperse biofilms. Biofilms are a major cause of a number of serious medical problems including chronic infections and medical device related infections. They develop on surfaces such as catheters, prosthetic implants, teeth, lungs and the urogenital tract. Biofilms are pervasive, costly to deal with and approximately 80% of all human bacterial infections involve biofilms. The healing of chronic wounds alone costs the Unites States health care system $20 Billion per year.
LATEST NEWS
June 8 , 2009
DispersinB® efficacy study published in the Journal of Antimicrobial Chemotherapy
WINNIPEG, Manitoba (June 8, 2009) - Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms is pleased to announce its research publication on the Company’s patented DispersinB® antibiofilm technology in the latest online edition of the Journal of Antimicrobial Chemotherapy. Read more
May 14, 2009
Kane Biotech Announces Closing of Private Placement OfferingKane Biotech Inc. (TSX-V: KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, has closed its previously announced private placement offering (the "Offering") with aggregate gross proceeds to the Company of $250,000 from the sale of 3,571,429 units ("Units") at a price of $0.07 per Unit. Each Unit is comprised of one common share of the Company (a “Share”) and one-half of one Share purchase warrant (a "Warrant"). Read more
March 9 , 2009
Washinton Post - Scientists Learning to Target Bacteria Where They Live Read moreFebruary 5, 2009
Kane Biotech Receives an Additional Contribution from NRC-IRAP to Develop its DispersinB® Antibiofilm Wound Gel ProductKane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, is pleased to announce that the National Research Council Industrial Research Assistance Program (NRC-IRAP) has increased its contribution to Kane Biotech by $150,000 bringing the total amount to $555,000. Read more
September 30 , 2008
Kane Biotech has Been Selected as one of Canada's Top 10™ Emerging Life Sciences Companies
Kane Biotech Inc. (TSX-V: KNE) is pleased to announce the Company has been selected as one of Canada’s Top 10™ Emerging Life Sciences companies. Winners will gather on October 7th at the Fairmont Chateau Laurier Hotel in Ottawa to meet local and regional investors, and prepare themselves for the first leg of the 2009 Investment Forum series. Read more
